Nephrotic Syndrome Market: Epidemiology, Therapies, Companies, DelveInsight | GlaxoSmithKline, Goldfinch Bio, Inc., Travere Therapeutics, Inc., Aurinia Pharmaceuticals, Bristol-Myers Squibb, ChemoCentryx, SynAct Pharma AB

Nephrotic Syndrome therapies, such as Atacicept, Atrasentan, and others, are expected to boost the Nephrotic Syndrome Market in the upcoming years.

DelveInsight has launched a new report on "Nephrotic Syndrome - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Nephrotic Syndrome, historical and forecasted epidemiology as well as the Nephrotic Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover about the Nephrotic Syndrome market report @ https://www.delveinsight.com/report-store/nephrotic-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Nephrotic Syndrome Market Report:

The Nephrotic Syndrome Market is expected to experience steady growth throughout the forecast period (2023-2034). The market size in the 7MM is projected to rise, driven by the introduction of new therapies.
According to DelveInsight's analysis, around 34% of the total diagnosed cases of Nephrotic Syndrome in the 7MM were from the United States. In 2022, the EU4 and the UK together accounted for nearly 367,000 diagnosed cases of Nephrotic Syndrome.
In the 7MM, the Nephrotic Syndrome Drugs Market was primarily comprised of corticosteroids, calcineurin inhibitors, ACE Inhibitors/ARBs, immunosuppressants, and others, generating approximately USD 401 million in 2022.
The total Nephrotic Syndrome Market is expected to grow during the forecast period, driven by the introduction of new, effective treatments such as Atacicept, Atrasentan, Gazyva/Gazyvaro (obinutuzumab), Zigakibart (BION-1301), and others.
In March 2025, the FDA expanded the approval of Furoscix to include the treatment of edema in patients with chronic kidney disease, including those with nephrotic syndrome. This expanded indication for furosemide injection (Furoscix; scPharmaceuticals, Inc.) is expected to be available by April 2025, following the FDA's acceptance of the supplemental new drug application in July 2024.
In January 2025, Hoffmann-La Roche initiated an open-label, randomized multicenter study to assess the efficacy, safety, and pharmacokinetics (PK)/pharmacodynamics (PD) of obinutuzumab compared to mycophenolate mofetil (MMF) in children and young adults (aged 2 to 25 years) with frequently relapsing nephrotic syndrome (FRNS) or steroid-dependent nephrotic syndrome (SDNS).
According to DelveInsight's estimates, the total number of diagnosed prevalent cases of Nephrotic Syndrome in the 7MM was around 786,000 in 2022, with projections indicating an increase throughout the forecast period.
In the United States, approximately 268,000 individuals were diagnosed with Nephrotic Syndrome in 2022, and this figure is expected to grow at an estimated compound annual growth rate (CAGR) during the study period from 2020 to 2034.
Key Nephrotic Syndrome companies such as GlaxoSmithKline, Goldfinch Bio, Inc., Travere Therapeutics, Inc., Aurinia Pharmaceuticals, Bristol-Myers Squibb, ChemoCentryx, SynAct Pharma AB, and others are evaluating new drugs for Nephrotic Syndrome to improve the treatment landscape.
Promising Nephrotic Syndrome therapies include Atacicept, Atrasentan, and others.

Nephrotic Syndrome Overview

Nephrotic Syndrome is a clinical condition characterized by significant proteinuria, which leads to hypoalbuminemia and subsequently causes hyperlipidemia, edema, and other complications associated with the syndrome. It can arise from a variety of underlying causes, including conditions like minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, lupus nephritis, diabetic nephropathy, infections, genetic disorders, certain medications, and more. Chronic nephrotic syndrome can lead to further complications, such as infections, malnutrition, and an increased risk of cardiovascular disease. Therefore, accurately identifying the specific cause is crucial for effective treatment and overall management.

From a pathological perspective, nephrotic syndrome involves changes in the structure and function of the glomeruli, the tiny filtration units in the kidneys responsible for removing waste and excess fluids from the blood. The main features of nephrotic syndrome include increased permeability of the glomerular filtration barrier, which results in the loss of proteins, especially albumin, in the urine.

Nephrotic Syndrome Market Outlook

Nephrotic syndrome is a group of symptoms indicating impaired kidney function, which include proteinuria, hypoalbuminemia, edema, hyperlipidemia, and various other related complications. The treatment of nephrotic syndrome involves addressing the underlying medical conditions that contribute to its development. Healthcare providers may recommend medications and dietary changes to control symptoms and manage complications.

Currently, there are no approved therapies specifically for nephrotic syndrome, and most treatment strategies rely on off-label approaches. Corticosteroids such as prednisone, cyclophosphamide, and cyclosporine are commonly used to induce remission in nephrotic syndrome. Diuretics help manage edema, while angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers are used to reduce proteinuria.

Advances in nephrotic syndrome treatment have improved patient care by incorporating lifestyle changes, medications, and procedures. New therapies, including monoclonal antibodies and drugs targeting APRIL and BAFF, show promise in enhancing patient outcomes. Ongoing research and clinical trials are paving the way for a brighter future in nephrotic syndrome treatment, offering hope for reduced morbidity and mortality.

Discover how the Nephrotic Syndrome market is rising in the coming years @ https://www.delveinsight.com/sample-request/nephrotic-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Nephrotic Syndrome Emerging Drugs
Atacicept: Vera Therapeutics
Atrasentan: Chinook Therapeutics/ Novartis

Scope of the Nephrotic Syndrome Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Nephrotic Syndrome Companies: GlaxoSmithKline, Goldfinch Bio, Inc., Travere Therapeutics, Inc., Aurinia Pharmaceuticals, Bristol-Myers Squibb, ChemoCentryx, SynAct Pharma AB, and others
Key Nephrotic Syndrome Therapies: Atacicept, Atrasentan and others
Nephrotic Syndrome Therapeutic Assessment: Nephrotic Syndrome current marketed and Nephrotic Syndrome emerging therapies
Nephrotic Syndrome Market Dynamics: Nephrotic Syndrome market drivers and Nephrotic Syndrome market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Nephrotic Syndrome Unmet Needs, KOL's views, Analyst's views, Nephrotic Syndrome Market Access and Reimbursement

To know what's more in our Nephrotic Syndrome report, visit https://www.delveinsight.com/report-store/nephrotic-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key benefits of the Nephrotic Syndrome Market Report:
Nephrotic Syndrome market report covers a descriptive overview and comprehensive insight of the Nephrotic Syndrome Epidemiology and Nephrotic Syndrome market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
The Nephrotic Syndrome market report provides insights into the current and emerging therapies.
The Nephrotic Syndrome market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Nephrotic Syndrome market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Nephrotic Syndrome market.

Got queries? Click here to know more about the Nephrotic Syndrome market Landscape https://www.delveinsight.com/sample-request/nephrotic-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Nephrotic Syndrome Patient Share (%) Overview at a Glance
5. Nephrotic Syndrome Market Overview at a Glance
6. Nephrotic Syndrome Disease Background and Overview
7. Nephrotic Syndrome Epidemiology and Patient Population
8. Country-Specific Patient Population of Nephrotic Syndrome
9. Nephrotic Syndrome Current Treatment and Medical Practices
10. Unmet Needs
11. Nephrotic Syndrome Emerging Therapies
12. Nephrotic Syndrome Market Outlook
13. Country-Wise Nephrotic Syndrome Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Nephrotic Syndrome Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Nephrotic Syndrome Market Outlook 2034 https://www.delveinsight.com/report-store/nephrotic-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Nephrotic Syndrome Pipeline Insights, DelveInsight

"Nephrotic Syndrome Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Nephrotic Syndrome market. A detailed picture of the Nephrotic Syndrome pipeline landscape is provided, which includes the disease overview and Nephrotic Syndrome treatment guidelines.

Contact Info:

Kritika Rehani, Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.